Search

Your search keyword '"Winer, Eric"' showing total 121 results
Start Over Author "Winer, Eric" Publication Year Range Last 10 years Publisher american society of clinical oncology
121 results on '"Winer, Eric"'

1. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.

Author

Loi, Sherene, Salgado, Roberto, Schmid, Peter, Cortes, Javier, Cescon, David W., Winer, Eric P., Toppmeyer, Deborah L., Rugo, Hope S., De Laurentiis, Michelino, Nanda, Rita, Iwata, Hiroji, Awada, Ahmad, Tan, Antoinette R., Sun, Yuan, Karantza, Vassiliki, Wang, Anran, Huang, Lingkang, Saadatpour, Assieh, Cristescu, Razvan, and Yearley, Jennifer

Subjects
TRIPLE-negative breast cancer, BIOMARKERS, TREATMENT effectiveness, HEMATOXYLIN & eosin staining, GENE expression profiling
Abstract

PURPOSE: In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS: Cohort A enrolled patients with disease progression after one or more systemic therapies for metastatic disease irrespective of PD-L1 status; Cohort B enrolled patients with previously untreated PD-L1–positive (combined positive score [CPS] ≥ 1) metastatic disease. The association between the following biomarkers as continuous variables and clinical outcomes (objective response rate [ORR], progression-free survival [PFS], and overall survival [OS]) was evaluated: PD-L1 CPS (immunohistochemistry), cluster of differentiation 8 (CD8; immunohistochemistry), stromal tumor-infiltrating lymphocyte (sTIL; hematoxylin and eosin staining), tumor mutational burden (TMB; whole-exome sequencing [WES]), homologous recombination deficiency-loss of heterozygosity, mutational signature 3 (WES), mutational signature 2 (apolipoprotein B mRNA editing catalytic polypeptide–like; WES), T-cell–inflamed gene expression profile (TcellinfGEP; RNA sequencing), and 10 non-TcellinfGEP signatures (RNA sequencing); Wald test P values were calculated, and significance was prespecified at α = 0.05. RESULTS: In the combined cohorts (A and B), PD-L1 (P =.040), CD8 (P <.001), sTILs (P =.012), TMB (P =.007), and TcellinfGEP (P =.011) were significantly associated with ORR; CD8 (P <.001), TMB (P =.034), Signature 3 (P =.009), and TcellinfGEP (P =.002) with PFS; and CD8 (P <.001), sTILs (P =.004), TMB (P =.025), and TcellinfGEP (P =.001) with OS. None of the non-TcellinfGEP signatures were associated with outcomes of pembrolizumab after adjusting for the TcellinfGEP. CONCLUSION: In this exploratory biomarker analysis from KEYNOTE-086, baseline tumor PD-L1, CD8, sTILs, TMB, and TcellinfGEP were associated with improved clinical outcomes of pembrolizumab and may help identify patients with mTNBC who are most likely to respond to pembrolizumab monotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

2. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.

Author

Francis, Prudence A., Fleming, Gini F., Láng, István, Ciruelos, Eva M., Bonnefoi, Hervé R., Bellet, Meritxell, Bernardo, Antonio, Climent, Miguel A., Martino, Silvana, Bermejo, Begoña, Burstein, Harold J., Davidson, Nancy E., Geyer Jr, Charles E., Walley, Barbara A., Ingle, James N., Coleman, Robert E., Müller, Bettina, Le Du, Fanny, Loibl, Sibylle, and Winer, Eric P.

Published
2023
Full Text
View/download PDF

3. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.

Author

Pagani, Olivia, Walley, Barbara A., Fleming, Gini F., Colleoni, Marco, Láng, István, Gomez, Henry L., Tondini, Carlo, Burstein, Harold J., Goetz, Matthew P., Ciruelos, Eva M., Stearns, Vered, Bonnefoi, Hervé R., Martino, Silvana, Geyer Jr, Charles E., Chini, Claudio, Puglisi, Fabio, Spazzapan, Simon, Ruhstaller, Thomas, Winer, Eric P., and Ruepp, Barbara

Published
2023
Full Text
View/download PDF

5. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study.

Author

Stavrou, Eleni, Qiu, Jeanna, Zafar, Affan, Tramontano, Angela C., Isakoff, Steven, Winer, Eric, Schrag, Deborah, and Manz, Christopher

Subjects
MEDICAL quality control, ACADEMIC medical centers, CROSS-sectional method, PHYSICIAN-patient relations, PHYSICIANS' attitudes, SURVEYS, WORKFLOW, ACCESS to information, PATIENT compliance, BREAST tumors, CANCER patient medical care, ONCOLOGISTS, TELEMEDICINE, OUTPATIENT services in hospitals
Abstract

PURPOSE The COVID-19 pandemic forced rapid adoption of telemedicine (TM) for breast oncology visits in the United States, but the appropriate role of postpandemic TM is uncertain. We sought to understand physician and advance practice practitioner perspectives on the use of TM for outpatient breast cancer care through an electronically administered survey. METHODS Breast medical oncology clinicians at two academic cancer centers and five satellite locations affiliated with the Dana Farber Cancer Institute and the Massachusetts General Cancer Center were invited to respond to a 21-question survey administered in September 2021 about clinicians' perceptions and attitudes toward TM during the previous 12 months. RESULTS Of the 71 survey invitations, 51 clinicians (36 physicians and 15 advance practice practitioners) provided survey responses (response rate = 72%). Ninety-two percent of respondents (n = 47) agreed that TM visits enhance patient care. Ninety-two percent of respondents (n = 46) also agreed that TM is valuable for early-stage breast cancer follow-up visits. Most respondents felt that there was no difference between TM and face-to-face (F2F) visits when it came to patient adherence, ease of ordering tests, ease of accessing patient records, and workflow outside of the visit (82%, 82%, 78%, and 53%, respectively). Fifty-one percent of respondents (n = 26) said that TM was better for timely access to follow-up appointments. Most respondents said that F2F visits were better for seeing physical problems, personal connection with patients, overall quality of visits, and patient-physician communication (100%, 75%, 65%, and 63%, respectively). CONCLUSION Breast clinicians believe that TM is a valuable tool to enhance outpatient breast cancer care. TM was felt to be appropriate for routine follow-up visits and second opinion consultations and is as good as or better than F2F visits for several routine aspects of breast cancer care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Author

Lipsyc-Sharf, Marla, de Bruin, Elza C., Santos, Katheryn, McEwen, Robert, Stetson, Daniel, Patel, Ashka, Kirkner, Gregory J., Hughes, Melissa E., Tolaney, Sara M., Partridge, Ann H., Krop, Ian E., Knape, Charlene, Feger, Ute, Marsico, Giovanni, Howarth, Karen, Winer, Eric P., Lin, Nancy U., and Parsons, Heather A.

Published
2022
Full Text
View/download PDF

7. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.

Author

Barroso-Sousa, Romualdo, Forman, Juliet, Collier, Katharine, Weber, Zachary T., Jammihal, Tejas R., Kao, Katrina Z., Richardson III, Edward T., Keenan, Tanya, Cohen, Ofir, Manos, Michael P., Brennick, Ryan C., Ott, Patrick A., Hodi, F. Stephen, Dillon, Deborah A., Attaya, Victoria, O'Meara, Tess, Lin, Nancy U., Van Allen, Eliezer M., Rodig, Scott, and Winer, Eric P.

Subjects
TRIPLE-negative breast cancer, IMMUNE checkpoint inhibitors, PROGRAMMED death-ligand 1, T helper cells, CIRCULATING tumor DNA, IPILIMUMAB
Abstract

PURPOSE: In metastatic triple-negative breast cancer (mTNBC), consistent biomarkers of immune checkpoint inhibitor (ICI) therapy benefit remain elusive. We evaluated the immune, genomic, and transcriptomic landscape of mTNBC in patients treated with ICIs. METHODS: We identified 29 patients with mTNBC treated with pembrolizumab or atezolizumab, either alone (n = 9) or in combination with chemotherapy (n = 14) or targeted therapy (n = 6), who had tumor tissue and/or blood available before ICI therapy for whole-exome sequencing. RNA sequencing and CIBERSORTx-inferred immune population analyses were performed (n = 20). Immune cell populations and programmed death-ligand 1 expression were assessed using multiplexed immunofluorescence (n = 18). Clonal trajectories were evaluated via serial tumor/circulating tumor DNA whole-exome sequencing (n = 4). Association of biomarkers with progression-free survival and overall survival (OS) was assessed. RESULTS: Progression-free survival and OS were longer in patients with high programmed death-ligand 1 expression and tumor mutational burden. Patients with longer survival also had a higher relative inferred fraction of CD8+ T cells, activated CD4+ memory T cells, M1 macrophages, and follicular helper T cells and enrichment of inflammatory gene expression pathways. A mutational signature of defective repair of DNA damage by homologous recombination was enriched in patients with both shorter OS and primary resistance. Exploratory analysis of clonal evolution among four patients treated with programmed cell death protein 1 blockade and a tyrosine kinase inhibitor suggested that clonal stability post-treatment was associated with short time to progression. CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes. In patients with mTNBC, responses to ICI-containing therapies were associated with high TMB; the presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer...

Author

Mayer, Erica L, Fesl, Christian, Hlauschek, Dominik, Garcia-Estevez, Laura, Burstein, Harold J, Zdenkowski, Nicholas, Wette, Viktor, Miller, Kathy D, Balic, Marija, Mayer, Ingrid A, Cameron, David, Winer, Eric P, Ponce Lorenzo, José Juan, Lake, Diana, Pristauz-Telsnigg, Gunda, Haddad, Tufia C, Shepherd, Lois, Iwata, Hiroji, Goetz, Matthew, and Cardoso, Fatima

Published
2022
Full Text
View/download PDF

10. Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.

Author

Collier, Katharine A., Asad, Sarah, Tallman, David, Jenison, Janet, Rajkovic, Andrei, Mardis, Elaine R., Parsons, Heather A., Tolaney, Sara M., Winer, Eric P., Lin, Nancy U., Ha, Gavin, Adalsteinsson, Viktor A., and Stover, Daniel G.

Subjects
CELL-free DNA, TRIPLE-negative breast cancer, SOMATIC mutation, METASTATIC breast cancer, CIRCULATING tumor DNA, PLATINUM, PROPORTIONAL hazards models, PRENATAL diagnosis
Abstract

PURPOSE: To determine whether specific somatic copy-number alterations detectable in circulating tumor DNA (ctDNA) from patients with metastatic triple-negative breast cancer (mTNBC) are associated with sensitivity to platinum chemotherapy. MATERIALS AND METHODS: In this secondary analysis of a large cohort of patients with mTNBC whose ctDNA underwent ultralow-pass whole-genome sequencing, tumor fraction and somatic copy-number alterations were derived with the ichorCNA algorithm. Seventy-two patients were identified who had received a platinum-based chemotherapy regimen in the metastatic setting. Gene-level copy-number analyses were performed with GISTIC2.0. Cytobands were associated with progression-free survival (PFS) to platinum chemotherapy using Cox proportional hazards models. The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium data sets were interrogated for frequency of significant cytobands in primary triple-negative breast cancer (pTNBC) tumors. RESULTS: Among 71 evaluable patients, 17q21 and 17q22 amplifications were most strongly associated with improved PFS with platinum chemotherapy. There were no significant differences in clinicopathologic features or (neo)adjuvant chemotherapy among patients with 17q22 amplification. Patients with 17q22 amplification (n = 17) had longer median PFS with platinum (7.0 v 3.8 months; log-rank P =.015) than patients without 17q22 amplification (n = 54), an effect that remained significant in multivariable analyses (PFS hazard ratio 0.37; 95% CI, 0.16 to 0.84; P =.02). Among 39 patients who received the nonplatinum chemotherapy agent capecitabine, there was no association between 17q22 amplification and capecitabine PFS (log-rank P =.69). In The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium, 17q22 amplification occurred in more than 20% of both pTNBC and mTNBC tumors, whereas 17q21 was more frequently amplified in mTNBC relative to pTNBC (16% v 8.1%, P =.015). CONCLUSION: The 17q22 amplicon, detected by ctDNA, is associated with improved PFS with platinum chemotherapy in patients with mTNBC and warrants further investigation. 17q22 amplification detected in ctDNA is associated with longer PFS to platinum in metastatic TNBC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Author

Connolly, Roisin M, Leal, Jeffrey P, Solnes, Lilja, Huang, Chiung-Yu, Carpenter, Ashley, Gaffney, Katy, Abramson, Vandana, Carey, Lisa A, Liu, Minetta C, Rimawi, Mothaffar, Specht, Jennifer, Storniolo, Anna Maria, Valero, Vicente, Vaklavas, Christos, Krop, Ian E, Winer, Eric P, Camp, Melissa, Miller, Robert S, Wolff, Antonio C, and Cimino-Mathews, Ashley

Published
2021
Full Text
View/download PDF

12. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

Author

Fernandez-Martinez, Aranzazu, Krop, Ian E., Hillman, David W., Polley, Mei-Yin, Parker, Joel S., Huebner, Lucas, Hoadley, Katherine A., Shepherd, Jonathan, Tolaney, Sara, Henry, N. Lynn, Dang, Chau, Harris, Lyndsay, Berry, Donald, Hahn, Olwen, Hudis, Clifford, Winer, Eric, Partridge, Ann, Perou, Charles M., and Carey, Lisa A.

Published
2020
Full Text
View/download PDF

14. Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.

Author

Vaz-Luis, Ines, Barroso-Sousa, Romualdo, Di Meglio, Antonio, Hu, Jiani, Rees, Rebecca, Sinclair, Natalie, Milisits, Lindsey, Leone, Jose Pablo, Constantine, Michael, Faggen, Meredith, Briccetti, Frederick, Block, Caroline, O'Neil, Kelly, Partridge, Ann, Burstein, Harold, Waks, Adrienne G., Trippa, Lorenzo, Tolaney, Sara M., Hassett, Michael, and Winer, Eric P.

Published
2020
Full Text
View/download PDF

15. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib.

Author

Batalini, Felipe, Moulder, Stacy L., Winer, Eric P., Rugo, Hope S., Lin, Nancy U., and Wulf, Gerburg M.

Subjects
HORMONE receptor positive breast cancer, BRAIN metastasis, BREAST cancer
Abstract

Activating mutations of I PIK3CA i are found in 25%-40% of estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancers (BC), and in 8% of ER-negative (ER-) BC.[1] [5] Two recent studies support the benefit of PI3K inhibition in combination with endocrine therapy. Brain MRI 6 weeks later demonstrated a 14% reduction in the sum of longest distances of measurable brain metastases (24% reduction in bidimensional areas) and regressions of nonmeasurable brain metastases. A recent study showed that I PIK3CA i -mutant BC not only has a higher probability to metastasize to the brain than nonmutant BC (31% I v i 17%) but also has shorter median overall survival after the diagnosis of CNS metastasis (0.5 I v i 1.1 year).[9] The high frequency of brain metastases and their poor prognosis raise the question whether PI3K inhibitors can be beneficial for patients with active brain metastases. Breast Cancer Res; 13: R125, 2011 9 Fitzgerald DM, Muzikansky A, Pinto C, et al: Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer. [Extracted from the article]

Published
2020
Full Text
View/download PDF

16. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial).

Author

Tung, Nadine, Arun, Banu, Hacker, Michele R., Hofstatter, Erin, Toppmeyer, Deborah L., Isakoff, Steven J., Borges, Virginia, Legare, Robert D., Isaacs, Claudine, Wolff, Antonio C., Marcom, Paul Kelly, Mayer, Erica L., Lange, Paulina B., Goss, Andrew J., Jenkins, Colby, Krop, Ian E., Winer, Eric P., Schnitt, Stuart J., and Garber, Judy E.

Published
2020
Full Text
View/download PDF

17. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).

Author

Hwang, E. Shelley, Hyslop, Terry, Hendrix, Laura H., Duong, Stephanie, Bedrosian, Isabelle, Price, Elissa, Caudle, Abigail, Hieken, Tina, Guenther, Joseph, Hudis, Clifford A., Winer, Eric, Lyss, Alan P., Dickson-Witmer, Diana, Hoefer, Richard, Ollila, David W., Hardman, Timothy, Marks, Jeffrey, Chen, Yunn-Yi, Krings, Gregor, and Esserman, Laura

Published
2020
Full Text
View/download PDF

19. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Author

Connolly, Roisin M., Leal, Jeffrey P., Solnes, Lilja, Huang, Chiung-Yu, Carpenter, Ashley, Gaffney, Katy, Abramson, Vandana, Carey, Lisa A., Liu, Minetta C., Rimawi, Mothaffar, Specht, Jennifer, Storniolo, Anna Maria, Valero, Vicente, Vaklavas, Christos, Krop, Ian E., Winer, Eric P., Camp, Melissa, Miller, Robert S., Wolff, Antonio C., and Cimino-Mathews, Ashley

Published
2019
Full Text
View/download PDF

21. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Author

Ramakrishna, Naren, Temin, Sarah, Chandarlapaty, Sarat, Crews, Jennie R., Davidson, Nancy E., Esteva, Francisco J., Giordano, Sharon H., Kirshner, Jeffrey J., Krop, Ian E., Levinson, Jennifer, Modi, Shanu, Patt, Debra A., Perlmutter, Jane, Winer, Eric P., and Lin, Nancy U.

Published
2018
Full Text
View/download PDF

23. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Author

Traina, Tiffany A., Miller, Kathy, Yardley, Denise A., Eakle, Janice, Schwartzberg, Lee S., O’Shaughnessy, Joyce, Gradishar, William, Schmid, Peter, Winer, Eric, Kelly, Catherine, Nanda, Rita, Gucalp, Ayca, Awada, Ahmad, Garcia-Estevez, Laura, Trudeau, Maureen E., Steinberg, Joyce, Uppal, Hirdesh, Tudor, Iulia Cristina, Peterson, Amy, and Cortes, Javier

Published
2018
Full Text
View/download PDF

24. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

Author

Stover, Daniel G., Parsons, Heather A., Ha, Gavin, Freeman, Samuel S., Barry, William T., Guo, Hao, Choudhury, Atish D., Gydush, Gregory, Reed, Sarah C., Rhoades, Justin, Rotem, Denisse, Hughes, Melissa E., Dillon, Deborah A., Partridge, Ann H., Wagle, Nikhil, Krop, Ian E., Getz, Gad, Golub, Todd R., Love, J. Christopher, and Winer, Eric P.

Published
2018
Full Text
View/download PDF

26. Phase II trial of pembrolizumab in patients with brain metastases.

Author

Brastianos, Priscilla Kaliopi, Kim, Albert Eusik, Giobbie-Hurder, Anita, Lee, Eudocia Quant, Lin, Nancy U., Overmoyer, Beth, Wen, Patrick Y., Nayak, Lakshmi, Cohen, Justine Vanessa, Dietrich, Jorg, Heist, Rebecca Suk, Krop, Ian E., Lawrence, Donald P., Mayer, Erica L., Winer, Eric P., Shih, Helen Alice, Oh, Kevin S., Cahill, Daniel P., Gerstner, Elizabeth R, and Sullivan, Ryan J.

Published
2023
Full Text
View/download PDF

27. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.

Author

Ligibel, Jennifer A., Ballman, Karla V., McCall, Linda Mackie, Goodwin, Pamela Jean, Weiss, Anna, Delahanty, Linda, Alfano, Catherine M., Crane, Tracy E, Neuhouser, Marian L., Spears, Patricia, Hershman, Dawn L., Paskett, Electra D., Hopkins, Judith O., Bernstein, Vanessa, Stearns, Vered, White, Julia R., Wadden, Thomas, Winer, Eric P., Partridge, Ann H., and Carey, Lisa A.

Published
2023
Full Text
View/download PDF

28. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Author

Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Goncalves, Rodrigo, Sanati, Souzan, Creighton, Chad J., DeSchryver, Katherine, Crouch, Erika, Brink, Amy, Watson, Mark, Luo, Jingqin, Tao, Yu, Barnes, Michael, Dowsett, Mitchell, Budd, G. Thomas, Winer, Eric, Silverman, Paula, Esserman, Laura, Carey, Lisa, and Ma, Cynthia X.

Published
2017
Full Text
View/download PDF

32. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Author

Dickler, Maura N., Barry, William T., Cirrincione, Constance T., Ellis, Matthew J., Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S., Lake, Diana E., Hahn, Olwen, Schneider, Bryan P., Tripathy, Debasish, Carey, Lisa A., Winer, Eric P., and Hudis, Clifford A.

Published
2016
Full Text
View/download PDF

35. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Author

Carey, Lisa A., Berry, Donald A., Cirrincione, Constance T., Barry, William T., Pitcher, Brandelyn N., Harris, Lyndsay N., Ollila, David W., Krop, lan E., Henry, Norah Lynn, Weckstein, Douglas J., Anders, Carey K., Singh, Baljit, Hoadley, Katherine A., Iglesia, Michael, Maggie Chon U. Cheang, Perou, Charles M., Winer, Eric P., Hudis, Clifford A., Krop, Ian E, and Cheang, Maggie Chon U

Published
2016
Full Text
View/download PDF

37. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission...

Author

Lin, Nancy U, Guo, Hao, Yap, Jeffrey T, Mayer, Ingrid A, Falkson, Carla I, Hobday, Timothy J, Dees, E Claire, Richardson, Andrea L, Nanda, Rita, Rimawi, Mothaffar F, Ryabin, Nicole, Najita, Julie S, Barry, William T, Arteaga, Carlos L, Wolff, Antonio C, Krop, Ian E, Winer, Eric P, and Van den Abbeele, Annick D

Published
2015
Full Text
View/download PDF

38. Phase II Study of Lapatinib in CombinationWith Trastuzumab in PatientsWith Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron...

Author

Lin, Nancy U., Hao Guo, Yap, Jeffrey T., Mayer, Ingrid A., Falkson, Carla I., Hobday, Timothy J., Dees, E. Claire, Richardson, Andrea L., Nanda, Rita, Rimawi, Mothaffar F., Ryabin, Nicole, Najita, Julie S., Barry, William T., Arteaga, Carlos L., Wolff, Antonio C., Krop, Ian E., Winer, Eric P., and Van den Abbeele, Annick D.

Published
2015
Full Text
View/download PDF

39. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB...

Author

Rugo, Hope S., Barry, William T., Moreno-Aspitia, Alvaro, Lyss, Alan P., Cirrincione, Constance, Leung, Eleanor, Mayer, Erica L., Naughton, Michael, Toppmeyer, Deborah, Carey, Lisa A., Perez, Edith A., Hudis, Clifford, and Winer, Eric P.

Published
2015
Full Text
View/download PDF

41. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Author

Isakoff, Steven J., Mayer, Erica L., Lei He, Traina, Tiffany A., Carey, Lisa A., Krag, Karen J., Rugo, Hope S., Liu, Minetta C., Stearns, Vered, Come, Steven E., Timms, Kirsten M., Hartman, Anne-Renee, Borger, Darrel R., Finkelstein, Dianne M., Garber, Judy E., Ryan, Paula D., Winer, Eric P., Goss, Paul E., and Ellisen, Leif W.

Published
2015
Full Text
View/download PDF

42. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial.

Author

Perez, Edith A., Thompson, E. Aubrey, Ballman, Karla V., Anderson, S. Keith, Asmann, Yan W., Kalari, Krishna R., Eckel-Passow, Jeanette E., Dueck, Amylou C., Tenner, Kathleen S., Jin Jen, Jian-Bing Fan, Geiger, XochiquetzalJ., McCullough, Ann E., Beiyun Chen, Jenkins, Robert B., Sledge, George W., Winer, Eric P., Gralow, Julie R., and Reinholz, Monica M.

Published
2015
Full Text
View/download PDF

43. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB...

Author

Sikov, William M., Berry, Donald A., Perou, Charles M., Singh, Baljit, Cirrincione, Constance T., Tolaney, Sara M., Kuzma, Charles S., Pluard, Timothy J., Somlo, George, Port, Elisa R., Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Carey, Lisa A., Hudis, Clifford A., and Winer, Eric P.

Published
2015
Full Text
View/download PDF

44. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal...

Author

Burstein, Harold J., Cirrincione, Constance T., Barry, William T., Chew, Helen K., Tolaney, Sara M., Lake, Diana E., Ma, Cynthia, Blackwell, Kimberly L., Winer, Eric P., and Hudis, Clifford A.

Published
2014
Full Text
View/download PDF

45. Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.

Author

O'Shaughnessy, Joyce, Schwartzberg, Lee, Danso, Michael A., Miller, Kathy D., Rugo, Hope S., Neubauer, Marcus, Robert, Nicholas, Hellerstedt, Beth, Saleh, Mansoor, Richards, Paul, Specht, Jennifer M., Yardley, Denise A., Carlson, Robert W., Finn, Richard S., Charpentier, Eric, Garcia-Ribas, Ignacio, and Winer, Eric P.

Published
2014
Full Text
View/download PDF

46. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Author

Perez, Edith A, Romond, Edward H, Suman, Vera J, Jeong, Jong-Hyeon, Sledge, George, Geyer Jr, Charles E, Martino, Silvana, Rastogi, Priya, Gralow, Julie, Swain, Sandra M, Winer, Eric P, Colon-Otero, Gerardo, Davidson, Nancy E, Mamounas, Eleftherios, Zujewski, Jo Anne, Wolmark, Norman, and Geyer, Charles E Jr

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results